23 results
424B5
SRZN
Surrozen Inc
25 Apr 24
Prospectus supplement for primary offering
4:28pm
repair, in a broad range of organs and tissues.
Our mission is to transform the treatment of serious disease by fully exploiting the Wnt pathway. We
424B3
SRZN
Surrozen Inc
7 Apr 23
Prospectus supplement
5:20pm
in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Overview
Our mission … .
BUSINESS
Overview
Our mission is to transform the treatment of serious disease by fully exploiting the Wnt pathway. We are discovering and developing
424B3
SRZN
Surrozen Inc
6 Apr 23
Prospectus supplement
5:15pm
this prospectus is a part.
Our mission is to transform the treatment of serious disease by fully exploiting the Wnt pathway. We are discovering and developing
POS AM
m0q68h0qjl1x ibxn
31 Mar 23
Prospectus update (post-effective amendment)
4:52pm
POS AM
dbxiasn7vkv3g6o9q
31 Mar 23
Prospectus update (post-effective amendment)
9:09am
424B3
uf5jb
5 Apr 22
Prospectus supplement
4:43pm
424B3
np2 w1ttfvl
30 Mar 22
Prospectus supplement
9:13pm
POS AM
a0tq61n aa
28 Mar 22
Prospectus update (post-effective amendment)
9:34pm
424B3
k47xpudqv99r
10 Nov 21
Prospectus supplement
12:00am
425
mklhyssu0rgvwcrkp
7 May 21
Business combination disclosure
5:27pm
8-K
EX-99.4
dzgz16e
15 Apr 21
Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration
8:42am
8-K
EX-99.3
2fccg8p
15 Apr 21
Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration
8:42am
8-K
EX-99.1
gk26 0roljeh25rr9
15 Apr 21
Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration
8:42am